ranolazine has been researched along with Acute Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davangeri, R; Hashilkar, NK; Majagi, SI; Naveena, R | 1 |
| Ameen, AM; Tawfik, MK | 1 |
| Braunwald, E; Karwatowska-Prokopczuk, E; McCabe, CH; Morrow, DA; Scirica, BM; Skene, A | 1 |
| Belardinelli, L; Braunwald, E; Gersh, BJ; Hedgepeth, CM; Hod, H; McCabe, CH; Molhoek, P; Morrow, DA; Murphy, SA; Scirica, BM; Verheugt, FW | 1 |
| Braunwald, E; Giugliano, RP | 1 |
| Melloni, C; Newby, LK | 1 |
1 review(s) available for ranolazine and Acute Disease
| Article | Year |
|---|---|
The year in non-ST-segment elevation acute coronary syndrome.
Topics: Acetanilides; Acute Disease; Age Factors; Aged; Biomarkers; Bone Morphogenetic Proteins; Cardiac Catheterization; Cardiology; Coronary Disease; Electrocardiography; Enzyme Inhibitors; Female; Fibrinolytic Agents; Glucose Metabolism Disorders; Growth Differentiation Factor 15; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Piperazines; Practice Guidelines as Topic; Quality Assurance, Health Care; Ranolazine; Risk Assessment; Sex Factors | 2007 |
2 trial(s) available for ranolazine and Acute Disease
| Article | Year |
|---|---|
Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
Topics: Acetanilides; Acute Disease; Aged; Angina, Unstable; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Ranolazine; Syndrome | 2006 |
Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischem
Topics: Acetanilides; Acute Disease; Aged; Angina Pectoris; Arrhythmias, Cardiac; Coronary Disease; Diabetic Angiopathies; Electrocardiography; Electrophysiology; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Placebos; Ranolazine; Tachycardia; Thrombolytic Therapy | 2007 |
3 other study(ies) available for ranolazine and Acute Disease
| Article | Year |
|---|---|
Effect of anti-inflammatory activity of ranolazine in rat model of inflammation.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carrageenan; Edema; Granuloma, Foreign-Body; Gum Arabic; Inflammation; Male; Random Allocation; Ranolazine; Rats, Wistar | 2018 |
Cardioprotective effect of ranolazine in nondiabetic and diabetic male rats subjected to isoprenaline-induced acute myocardial infarction involves modulation of AMPK and inhibition of apoptosis.
Topics: Acute Disease; AMP-Activated Protein Kinases; Animals; Apoptosis; Blood Glucose; Cardiotonic Agents; Diabetes Mellitus, Experimental; Electrocardiography; Glycated Hemoglobin; Isoproterenol; Male; Myocardial Infarction; Oxidative Stress; Ranolazine; Rats; Rats, Wistar | 2019 |
Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Topics: Acetanilides; Acute Coronary Syndrome; Acute Disease; Angina Pectoris; Cardiovascular Agents; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Quality of Life; Randomized Controlled Trials as Topic; Ranolazine; Recurrence; Sex Factors; Thrombolytic Therapy | 2008 |